Category Archives: Mesenchymal Stem Cells

Bioengineers from Brigham and Women's Hospital (BWH) with collaborators at the pharmaceutical company Sanofi have identified small molecules that can be used to program stem cells to home in on sites of damage, disease and inflammation. The techniques used to find and test these small molecules may represent important tools in advancing cell-based therapy, offering a new strategy for delivering cells to the right locations in the body. The results of their work appear online this week in Cell Reports. Through a collaborative research project, the research team tested more than 9,000 compounds, and used a multi-step approach -- including a sophisticated microfluidics set up and novel imaging technique -- to narrow in on and test the most promising compounds. "There are all kinds of techniques and tools that can be used to manipulate cells outside of the body and get them to do almost anything we want, but once we transplant cells we lose complete control over them," said co-senior author Jeff Karp, PhD, an associate professor at BWH, Harvard Medical School, and principal faculty at the Harvard Stem Cell Institute. "Through this collaboration, we've been able to identify small molecules that can be used to treat cells outside … Continue reading →

FAQ Part 3: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS) The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation have announced a $4.2 million grant in support of the MEse... By: MSSocietyCanada … Continue reading →

PARMA and MODENA, Italy, February 23, 2015 /PRNewswire/ -- The collaborationbetween a public excellent researchcenteranda solidprivate pharmaceuticalcompany allowed toachievean extraordinary result, entirely "made in Italy":the first medicinal productcontainingstem cellsapproved in the Western world The European Commission has granted a conditional marketing authorization, under Regulation (EC) No 726/2004, to Holoclar, an advanced therapy based on autologous stem cells and capable to restore the eyesight of patients with severe cornea damage. Holoclar is manufactured by Holostem Terapie Avanzate (HolostemAdvanced Therapies) - a spin-off of the University of Modena and Reggio Emilia - at the Centre for Regenerative Medicine "Stefano Ferrari" (CMR) of the same University. (Logo: http://photos.prnewswire.com/prnh/20150223/731609-a ) (Logo: http://photos.prnewswire.com/prnh/20150223/731609-b ) (Logo: http://photos.prnewswire.com/prnh/20150223/731609-c ) "Holoclaris theveryfirstmedicinalproductbased onstem cellsto beapproved andformallyregisteredin the Western world," states AndreaChiesi, Director of R&D Portfolio Management of Chiesi Farmaceutici S.p.A. and CEO of Holostem Terapie Avanzate. "This record," continues AndreaChiesi,"shows that thepartnershipbetween the public and privatesectorsis not only possible,butisprobably the best strategy for the development of stem cell-based regenerative medicine, particularly when autologous cells are used.Holostemisnowconsideredasabusiness modeltotranslate into clinicstheresultsobtained byscientific researchin this field." Underlying Holoclar are more than 20 years of excellence in research, conducted by a team of internationally renowned scientists in the field of epithelial stem … Continue reading →

CryoSave, part of ESPERITE, is the only private cord blood bank sponsoring a GCPclinical trial according to GMP-ATMP international guidelines CryoSave leads and sponsors a multicentre clinical trial following GCP-ICHstandards, for investigation of new treatment of Cerebral Palsy using dual infusionof two types of stem cells derived from umbilical cord blood and cord tissueprocessed by CryoSave Geneva, Switzerland - 23 February 2015 The clinical trial aims to demonstrate safety and preliminary efficacy of sequential intravenousinfusion of the ex vivo expanded mesenchymal stem cells (MSC) derived from cord tissue and thecord blood stem cells. The study will use, for the first time in clinical research, autologous MSC derived from cryopreserved cord tissue. The clinical trial, sponsored by CryoSave, will be performedin collaboration with Professor Manuel Ramrez Orellana, the Principal Investigator, and ProfessorLuis Madero, the Clinical Supervisor from the University Hospital Nio Jesus in Madrid, Spain. Cerebral Palsy is a devastating disease diagnosed in 1 per 326 children according to CDC, with noavailable treatment. 17 Million people worldwide live affected by cerebral Palsy (CPIRF). 26 BillionUSD are spent every year to accommodate the life of these patients in the US (WHO). Original post: ESPERITE (Euronext ESP) pioneers first treatment worldwide of Cerebral … Continue reading →

PRESS RELEASE TiGenix's Phase III trial design for Cx601 endorsed by President-Elect of ECCO Leuven (BELGIUM) - 23 February, 2015 -TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that Dr Julian Pans, a leading clinical specialist in inflammatory bowel disease, endorsed the design of the Company's Phase III trial of Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease during his presentation last week at the 10th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) held in Barcelona, Spain. Cx601 is a suspension of allogeneic expanded adipose-derived stem cells (eASCs) delivered locally through intra-lesional injection that is being developed for the treatment of perianal fistulas in Crohn's disease patients. Such fistulas cause severe complications and are difficult to manage, and have a significant negative impact on patient quality of life and psychological well-being. There is currently no effective treatment. In 2009, the European Commission granted Cx601 orphan designation for the treatment of anal fistulas, recognising the debilitating nature of the disease and the lack of treatment options. TiGenix is … Continue reading →

What is Bone Marrow Aspirate Concentrate (BMAC) in Stem Cell Therapy? Dr. McKenna explains bone marrow aspirate concentrate (BMAC). BMAC contains stem cells and growth factors that can build blood supply and heal tissue. For more information: http://www.rmiclinic.com... By: Riordan-McKenna Institute … Continue reading →

Stem Cell Therapy Using Fat Cells - Howard Beach, Ozone Park, Queens NY - Dr. Benjamin Bieber, MD Regenerative Medicine - Dr. Benjamin Bieber, MD - Howard Beach, Ozone Park, Queens NY http://www.crossbaypmr.com Phone: (718) 835-0100 Stem Cell Therapy Using Fat Cells Dr. Benjamin... By: wpv wpvmedia … Continue reading →

Ryan Benton Discusses Stem Cell Therapy for Duchenne's Muscular Dystrophy Ryan Benton is the first patient in the United States to receive human umbilical cord-derived mesenchymal stem cell therapy for Duchenne's muscular dystrophy. The US FDA granted Ryan this... By: http://www.cellmedicine.com … Continue reading →

Stem Cell Therapy for Liver Failure Cirrhosis Kidney Damage - 6 Months After Stemcell Transplant Bruce from Perth Australia give us an update 6 Months After his cord Mesenchymal stem cell treatment for Iiver cirrhosis, kidney complications in Thailand: More here: http://stemcellthailand.org/th... By: Regeneration Center of Thailand … Continue reading →

Jeff Dienhart took a deep breath. Painfully. The tubes from his oxygen tank shifted slightly near his nostrils as he began to speak. "I was originally diagnosed with cystic fibrosis at the age of 17," Dienhart said matter-of-factly. "At that time, life expectancy for someone with my disease was to live into your early 20s." At 44, Dienhart, an assistant coach for the Lafayette Central Catholic Knights girls basketball team, long ago beat those odds. He crouched forward and struggled to take another deep breath, no longer able to hide an illness he used to be embarrassed about. Central Catholic assistant girls basketball coaches Jeff Dienhart, foreground, and Dave Crandall watch the action as the Knights host Guerin Catholic on Jan. 30. It was the first game for Dienhart in quite a while, as he had spent the better part of the month of January in the hospital. Dienhart is set to receive stem cell treatment in the Dominican Republic to hopefully assist in his battle with cystic fibrosis. (Photo: John Terhune/Journal & Courier) "Basically, his day is: Wake up, take care of himself and go to basketball," said his son, Drew Dienhart. The coach has defied other statistics as … Continue reading →